Naturally Optimized Human Antibodies®

Multi-species, genetically engineered platforms for generation of diverse mono- and bispecific fully human antibodies

Ligand's OmniAb® platforms - OmniRat®, OmniMouse® and OmniFlic® - are based on novel, transgenic rodents that produce highly diversified antibody repertoires and offer accelerated discovery of fully human antibodies that are naturally optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity - Naturally optimized human antibodies®.

OmniAb includes the industry’s only rats for generation of mono- and bispecific human antibodies, OmniRat and OmniFlic. OmniMouse provides a complementary murine system for broader epitope coverage. All three platforms have complete freedom-to-operate and allow generation of antibodies specific for all targets and indications globally, unlike some genetically engineered mice on the market. Around 30 biopharmaceutical companies and universities have taken unlimited access to the OmniAb platforms. OmniAb antibodies have been generated against well over 100 targets and several are in clinical development in the US, Europe and Asia just a few years after the platforms where launched.

Beginning in 2008, OMT developed a novel rodent immunoglobulin gene knock-out technology and in 2009 reported generation of rats with completely inactivated immunoglobulin loci in the journal Science. Subsequent insertion of recombinant immunoglobulin loci resulted in OmniRat animals that were demonstrated to express a diverse repertoire of antibodies with fully human idiotypes as well as wildtype animals produce normal antibodies, another scientific-first. Based on its experience with OmniRat, OMT later developed OmniMouse and OmniFlic.

OmniAb animals are bred on multiple genetic backgrounds by certified, international breeders. OmniAb antibody discovery services are available from Ligand approved contract research organizations (CROs) in the US, Europe and Asia. These OmniDeep® services offer the most cost-efficient way to generate and characterize therapeutic OmniAb antibodies and are contracted directly with the providers. For more information on the most current technologies and offerings, please see www.omnideep.com.

Partners

Merck
Pfizer
Celgene
Amgen
Genmab
Janssen
FivePrime
Aptevo Therapeutics
SeattleGenetics
Symphogen
Armo Biosciences
Hanall Pharmaceutical
Gloria Pharmaceuticals
Tizona
ABBA
F-star
Gilead
Ono
AbbVie
BlueBirdBio
Charite
Genentech
Roche
Teneo
Teva

OmniAb is partnered with a range of large and small biopharmaceutical companies globally. For more information, including regarding OmniAb platform access, please E-mail omniab@ligand.com.